T1	Treatment 48 58	ipilimumab
T2	Treatment 670 877	received open-label ipilimumab (10 mg/kg every 3 weeks for four doses) and were randomized to receive concomitant blinded prophylactic oral budesonide (9 mg/d with gradual taper through week 16) or placebo
T3	Treatment 1081 1087	genes.
T4	Treatment 1088 1098	Ipilimumab
T5	Treatment 1535 1558	Prophylactic budesonide
